Status:

UNKNOWN

A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Lead Sponsor:

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Conditions:

Acute Gout

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine the efficacy and safety of recombinant anti-IL-1β humanized monoclonal antibody injection in Chinese participants with acute gout.

Detailed Description

Study SSGJ-613-AG-III-01 is a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group study examining the effect of recombinant anti-IL-1β humanized monoclonal ...

Eligibility Criteria

Inclusion

  • Must be 18 Years to 75 Years, both male and female.
  • BMI ≤35 kg/m2.
  • Meeting the American College of Rheumatology (ACR) 2015 criteria for the classification of acute arthritis of primary gout.
  • History of ≥ 3 gout flares within the 12 months prior to study randomization.
  • Onset of current acute gout flare within 4 days prior to study screening.
  • Screening pain intensity of the Target Joint ≥ 50 mm on the 0-100 mm VAS.
  • Contraindicated, intolerant or lack efficacy to NSAIDs and/or colchicine.
  • Accept uric acid lowering treatment according to the requirements of the protocol.

Exclusion

  • Gout caused by radiotherapy/chemotherapy, lead, organ transplantation, tumors, etc.
  • Evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis.
  • Presence of severe renal function impairment.
  • Intolerance of subcutaneous and intramuscular injection.
  • Known presence or suspicion of active or recurrent bacterial, fungal or viral infection at the time of enrollment.
  • History of malignant tumor within 5 years before screening.
  • Live vaccinations within 8 weeks prior to the start of the study.
  • Use of forbidden therapy.

Key Trial Info

Start Date :

December 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2025

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT06169891

Start Date

December 1 2023

End Date

November 1 2025

Last Update

December 14 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.